Nm

Global and China Passenger Car Cell to Pack, Cell To Chassis and Cell to Body Integrated Battery Industry Report 2024: Currently Only Tesla, BYD, Leapmotor and Xpeng have Released CTC/CTB Technology - ResearchAndMarkets.com

Retrieved on: 
月曜日, 4月 8, 2024
Vehicle Technology, EV, Electric Vehicles, Other Energy, Alternative Energy, Alternative Vehicles, Fuels, Batteries, General Automotive, Energy, Technology, Automotive, Automotive Manufacturing, Other Automotive, Manufacturing, Leapmotor, JAC, CIB, Volvo, CTB, BYD, Model Y, Cell, Original equipment manufacturer, Acceleration, EVS, Volkswagen, Nm, Gigafactory Texas, CTC, CATL, CTP, SAIC, Electric battery

The "Passenger Car CTP (Cell to Pack), CTC (Cell To Chassis) and CTB (Cell to Body) Integrated Battery Industry Report, 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Passenger Car CTP (Cell to Pack), CTC (Cell To Chassis) and CTB (Cell to Body) Integrated Battery Industry Report, 2024" report has been added to ResearchAndMarkets.com's offering.
  • Currently only four automakers Tesla, BYD, Leapmotor and Xpeng have released CTC/CTB technology and applied it in production models.
  • Leapmotor: In April 2022 Leapmotor released CTC technology, and first applied it to the production model Leapmotor C01.
  • In addition to Tesla, BYD, Leapmotor and Xpeng, Xiaomi, Volkswagen, Volvo, JAC and SAIC all make layout of CTC technology.

Global and China Passenger Car Cell to Pack, Cell To Chassis and Cell to Body Integrated Battery Industry Report 2024: In 2023, CTP Technology was Seen in Nearly 50% of New Energy Vehicles Sold

Retrieved on: 
金曜日, 3月 15, 2024
Leapmotor, JAC, CIB, Volvo, CTB, BYD, Model Y, Cell, Original equipment manufacturer, Acceleration, EVS, Volkswagen, Nm, Gigafactory Texas, CTC, CATL, CTP, SAIC, Electric battery

DUBLIN, March 14, 2024 /PRNewswire/ -- The "Passenger Car CTP (Cell to Pack), CTC (Cell To Chassis) and CTB (Cell to Body) Integrated Battery Industry Report, 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 14, 2024 /PRNewswire/ -- The "Passenger Car CTP (Cell to Pack), CTC (Cell To Chassis) and CTB (Cell to Body) Integrated Battery Industry Report, 2024" report has been added to ResearchAndMarkets.com's offering.
  • In 2023, CTP (Cell to Pack) technology was seen in nearly 50% of new energy vehicles sold.
  • CTC technology however requires battery cells with high intrinsic safety, and this needs to enhance thermal stability of battery cell materials.
  • In addition to Tesla, BYD, Leapmotor and Xpeng, Xiaomi, Volkswagen, Volvo, JAC and SAIC all make layout of CTC technology.

Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting

Retrieved on: 
火曜日, 9月 19, 2023
PK, DNA, NTCP, International, Assembly, DL, Biotechnology, HDV, CAM, Nm, Viral, Hepatitis B, Hepatitis B virus, Doctor of Philosophy, Liver cancer, Plasma, Patient, Liver, Poster, Viral hepatitis, HBV, Mutation, Vaccine

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that the company will present new preclinical data from multiple hepatitis B virus (HBV) and hepatitis D virus (HDV) pipeline programs at the 2023 International HBV Meeting taking place in Kobe, Japan, September 19-23, 2023.

Key Points: 
  • At the meeting, one oral presentation will highlight progress in the company’s HBV/HDV oral entry inhibitor program including activity, selectivity and pharmacokinetic (PK) data that support advancement towards development candidate nomination.
  • A second oral presentation reports new data for ABI-4334 (4334), Assembly Bio’s most potent capsid assembly modulator (CAM) with a potential best-in-class profile, describing the prevention of HBV DNA integration in vitro.
  • The poster presentation, from the company’s interferon-α receptor (IFNAR) agonist program, characterizes small molecule IFNAR agonists that closely mimic interferon-α’s signaling.
  • In patients with chronic HBV infection, HBV DNA integration has been linked to the development of liver cancer.

Marvell Introduces Industry's First 5nm Multi-Gigabit PHY Platform

Retrieved on: 
水曜日, 8月 16, 2023
Application-specific integrated circuit, IEEE 802.11ac-2013, Wi-Fi, Data-rate units, IEEE 802.1AE, IEEE 802.11be, PHY, Chosen-ciphertext attack, Marvell, DSP, Wi-Fi 6, Physics, Medium access control, IEEE, 6E, MRVL, Socs, Algorithm, Marvell Technology, AI, Copper, Nm, AR, Internet service provider, Mobile phone

5nm multi-gigabit copper Ethernet PHY platform based on a new architecture to deliver dramatic reductions in power.

Key Points: 
  • 5nm multi-gigabit copper Ethernet PHY platform based on a new architecture to deliver dramatic reductions in power.
  • The product is the first in a portfolio of 5nm products from Marvell to enable higher bandwidth and energy efficient enterprise networks.
  • Marvell's 5nm multi-gig PHY platform is based around optimized circuit designs, custom digital logic, enhanced DSP algorithms and other innovations to deliver 10 Gbps performance at half the power of previous generation devices from Marvell.
  • "Our first to market new 5nm multi-gigabit copper PHY platform delivers a leap in performance and capabilities over those found on the market today," said Venu Balasubramonian, vice president of product marketing, High Speed Connectivity and PHY Business Unit at Marvell.

Mitsubishi Motors: World Premiere of the All-New Triton One-ton Pickup Truck

Retrieved on: 
水曜日, 7月 26, 2023
Diamond, Sport, Shoulder, ASEAN, Light, White Diamond, Solid white (chicken plumage), SUV, Titanium, Start-stop system, Risk, Mitsubishi Motors Brasil, Acceleration, HDC, Fatigue, Software, FCM, Maintenance, Particular, AYC, 4L, Atmosphere, Smartphone, Mitsubishi Motors, Torque, Traction control system, Snow, Soyuz (spacecraft), 6A, 4WD, Diesel fuel, System, Super Select, Hill-holder, Safety, ACC, Posture, Stroke, Vibration, ASTC, LSD, History, Tablet, Traction, Limited-slip differential, Slipping, HSA, LCA, Pascal (unit), Movement, BSW, Stiffness, Nm, Body size and species richness, Automotive industry, Explosive, Road, Rail transport, Electric motor, Telescopic sight, Coordinate system, Triton

Special website for the all-new Triton: www.mitsubishi-motors.com/en/products/triton

Key Points: 
  • Special website for the all-new Triton: www.mitsubishi-motors.com/en/products/triton
    Mitsubishi Motors has produced approximately 5.6 million pickup trucks spanning five generations over the 45 years since its first launch in 1978.
  • With a record of sales in 150 countries, the pickup truck is a global strategic vehicle for Mitsubishi Motors.
  • Now in its sixth generation, the all-new Triton is fully redesigned for the first time in nine years.
  • The all-new Triton combines agility with the Mitsubishi Motors' robust design to create an imposing look while expressing the toughness and powerfulness expected of a pickup truck.

Sporos BioDiscovery Presents Preclinical Data on Differentiated TEAD Inhibitor Program, SPR1, at the 34th EORTC-NCI-AACR Symposium

Retrieved on: 
木曜日, 10月 27, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Biotechnology, LLC, Goal, Exception, RTK, Hippopotamus, MAPK, Combination therapy, KRAS, Factor X, COVID-19, Patient, IND, MTD, Research, Poster, TEAD, Neoplasm, Program, MEK, Tumor microenvironment, Family, Patent, Nm, EGFR, Safety, Pharmaceutical industry, Fine chemical

We were excited to present preclinical data from SPR1, a next-generation, finely tuned TEAD inhibitor program, with a unique TEAD isoform selectivity that we believe sets it apart from other TEAD inhibitors and offers a potential best-in-class profile.

Key Points: 
  • We were excited to present preclinical data from SPR1, a next-generation, finely tuned TEAD inhibitor program, with a unique TEAD isoform selectivity that we believe sets it apart from other TEAD inhibitors and offers a potential best-in-class profile.
  • Our data supports our initiative to move SPR1 into clinical development with a goal of filing an IND before the end of 2023.
  • The poster presents the first disclosure of SPR1, Sporos TEAD inhibitor program.
  • Sporos' TEAD inhibitors yield rapid regression even in very large pre-clinical tumors, a first in the TEAD-inhibitor space.

Attralus Presents Preclinical Data Demonstrating Potent Binding to All Types of Systemic and Cerebral Amyloid by its Pan-Amyloid Removal Candidate AT-04 at 18th International Symposium on Amyloidosis

Retrieved on: 
水曜日, 9月 7, 2022
Patient, University, THP-1 cell line, Central nervous system disease, Technology, Neurodegeneration, Degenerative disease, Transferrin saturation, Liver, Awareness, Brain, ATTR, Kidney, ISA, Immunoglobulin G, Heart, Mouse, Tissue, AL, EC50, Serum, Nm, Phagocytosis, Amyloid, Alzheimer's disease, Cerebral amyloid angiopathy, MD, GLOBE, FC, PAR, Company, Immune system, Therapy, Iodine, CNS, Forward-looking statement, International Symposium on Endovascular Therapy, AA, Medical imaging, Vaccine, Amyloidosis, Hepatosplenic T-cell lymphoma

The data was included in a poster presentation at the 18th International Symposium on Amyloidosis (ISA) taking place September 4-8, 2022, in Heidelberg, Germany.

Key Points: 
  • The data was included in a poster presentation at the 18th International Symposium on Amyloidosis (ISA) taking place September 4-8, 2022, in Heidelberg, Germany.
  • The latest preclinical data for AT-04 demonstrate potent binding to multiple types of systemic amyloid, as well as A, tau, and -synuclein aggregates, amyloid pathologies common in neurodegenerative disorders.
  • This binding of AT-04 to amyloid can induce phagocytosis, which is anticipated to lead to clearance of amyloid from the body.
  • The PAR-peptide mediates binding to all types of amyloid and the Fc stimulates the immune system to remove amyloid.

Onconova Therapeutics Announces Abstract at the ASCO Annual Meeting Highlighting Narazaciclib’s Differentiated Inhibitory and Improved Safety Profile in Preclinical Models

Retrieved on: 
木曜日, 5月 26, 2022
ARK, Shift, Company, Annual general meeting, Private Securities Litigation Reform Act, Patient, Cellular thermal shift assay, NASDAQ, 29, Therapy, INKA, Society, American Society of Clinical Oncology, FDA, CETSA, Securities Act of 1933, Securities Exchange Act of 1934, Metastasis, Nm, CDK, Terminology, ASCO, Ribociclib, Drug Quality and Security Act, Drug resistance, Phosphorylation, Nivolumab, Cancer, Diarrhea, Risk, Annual report, GLOBE, Pharmaceutical industry, CSF1R

Featured in the abstract are preclinical data from in vitro and cell-based assays that demonstrate how narazaciclibs inhibitory profile differentiates it from the FDA-approved CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib.

Key Points: 
  • Featured in the abstract are preclinical data from in vitro and cell-based assays that demonstrate how narazaciclibs inhibitory profile differentiates it from the FDA-approved CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib.
  • Narazaciclibs inhibitory activity against GSK3, a kinase whose inhibition putatively causes tolerability issues related to diarrhea, is ~29 times less than that of abemaciclib.
  • A copy of the abstract, titled, Narazaciclibs kinase inhibitory activity is differentiated from approved CDK4/6 inhibitors in preclinical models, is available on the ASCO Annual Meeting website .
  • Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer.

BridGene Biosciences' IMTAC ™ Small Molecule Discovery Platform Featured in Multiple Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
木曜日, 10月 7, 2021
SAR, TEAD, Sunitinib, SAN, Transforming protein RhoA, Drug discovery, Conference, Liposarcoma, TCGA, Cell, Nm, Protein, Glioblastoma, Diagnosis, Cancer, Immortalised cell line, NF2, Education, American Association for Cancer Research, Entrepreneurship, The Cancer Genome Atlas, Factor X, ELISA, WDR5, AACR, GTPase, Stomach, CDH1, Gene expression, CEO, Mesothelioma, MLL1, American Association, Association, IC50, Disease, Patient, Science, DGC, Research, Technology, Pharmaceutical industry, Vaccine, Fine chemical, Mobile phone

The presentations detail the company's proprietary small molecule discovery platform, IMTACTM (Isobaric Mass Tagged Affinity Characterization) and its use in BridGene's latest discovery of therapeutic candidates and the identification of new targets for approved small-molecule drugs.

Key Points: 
  • The presentations detail the company's proprietary small molecule discovery platform, IMTACTM (Isobaric Mass Tagged Affinity Characterization) and its use in BridGene's latest discovery of therapeutic candidates and the identification of new targets for approved small-molecule drugs.
  • "This is among the most prominent scientific gatherings addressing drug discovery and molecular targets.
  • Overall, our presentations describe our IMTAC platform technology and its capabilities, the discovery of novel small-molecule inhibitors for undruggable targets, and the identification of previously unknown targets for approved small-molecule drugs."
  • BridGene used the IMTAC platform to screen its unique covalent library against live-cell proteomes and discovered small-molecule ligands for WDR5.